Advertisement for orthosearch.org.uk
Results 101 - 120 of 208
Results per page:
Bone & Joint 360
Vol. 8, Issue 2 | Pages 31 - 33
1 Apr 2019


The Bone & Joint Journal
Vol. 101-B, Issue 1_Supple_A | Pages 1 - 1
1 Jan 2019
Greenwald AS


The Bone & Joint Journal
Vol. 100-B, Issue 2 | Pages 152 - 160
1 Feb 2018
Subramanyam KN Khanchandani P Tulajaprasad PV Jaipuria J Mundargi AV

Aims

The aims of this study were to compare the efficacy and safety of intra-articular and intravenous (IV) tranexamic acid (TXA) in controlling perioperative blood loss in total knee arthroplasty (TKA) using a randomized, double-blinded equivalence trial.

Patients and Methods

A total of 182 patients aged between 45 and 75 years undergoing unilateral TKA at a tertiary centre were randomized to receive TXA, either 1.5 g intra-articularly after closure of the wound (n = 91) or two doses of 10 mg/kg IV (n = 91). The primary outcome measure was the reduction in the level of haemoglobin (Hb) in the blood on the fifth postoperative day. Secondary outcome measures were the total, visible, and hidden blood losses (TBL, VBL, HBL). We assumed equivalence of the primary outcome in both routes with a margin of ± 0.35gm/dl. Block randomization using computer-generated random numbers was used. The patients and the assessor of outcome were blinded.


The Bone & Joint Journal
Vol. 101-B, Issue 4 | Pages 396 - 402
1 Apr 2019
Ji B Wahafu T Li G Zhang X Wang Y Momin M Cao L

Aims

Single-stage revision is not widely pursued due to restrictive inclusion criteria. In this study, we evaluated the results of single-stage revision of chronically infected total hip arthroplasty (THA) using broad inclusion criteria and cementless implants.

Patients and Methods

Between 2010 and 2016, 126 patients underwent routine single-stage revision with cementless reconstruction with powdered vancomycin or imipenem poured into the medullary cavity and re-implantation of cementless components. For patients with a culture-negative hip, fungal infections, and multidrug-resistant organisms, a direct intra-articular infusion of pathogen-sensitive antibiotics was performed postoperatively. Recurrence of infection and clinical outcomes were evaluated. Three patients died and 12 patients (none with known recurrent infection) were lost to follow-up. There were 111 remaining patients (60 male, 51 female) with a mean age of 58.7 (sd 12.7; 20 to 79).


Bone & Joint 360
Vol. 8, Issue 1 | Pages 40 - 42
1 Feb 2019


Bone & Joint 360
Vol. 7, Issue 5 | Pages 36 - 38
1 Oct 2018


The Bone & Joint Journal
Vol. 98-B, Issue 1_Supple_A | Pages 98 - 100
1 Jan 2016
Su EP Su S

During the last ten years, greater attention has been given to the management of peri-operative blood loss after total knee arthroplasty (TKA), as it is a modifiable outcome that has a significant effect on the rate of complications, the recovery, and the economic burden. Blood loss after TKA has been greatly reduced during this time, thereby dramatically reducing the rates of allogeneic transfusion. This has significantly reduced the complications associated with transfusion, such as fluid overload, infection, and increased length of stay.

The greatest advent in lowering peri-operative blood loss after TKA has been the introduction of tranexamic acid, which reduces blood loss without increasing the risk of thromboembolic events.

This paper discusses the ways of reducing blood loss after TKA, for which a multimodal algorithm, with pre-, intra- and post-operative measures, has been adopted at our institution.

Cite this article: Bone Joint J 2016;98-B(1 Suppl A):98–100.


The Bone & Joint Journal
Vol. 100-B, Issue 8 | Pages 1025 - 1032
1 Aug 2018
Wang D Wang H Luo Z Meng W Pei F Li Q Zhou Z Zeng W

Aims

The aim of this study was to identify the most effective regimen of multiple doses of oral tranexamic acid (TXA) in achieving maximum reduction of blood loss in total knee arthroplasty (TKA).

Patients and Methods

In this randomized controlled trial, 200 patients were randomized to receive a single dose of 2.0 g of TXA orally two hours preoperatively (group A), a single dose of TXA followed by 1.0 g orally three hours postoperatively (group B), a single dose of TXA followed by 1.0 g three and nine hours postoperatively (group C), or a single dose of TXA followed by 1.0 g orally three, nine, and 15 hours postoperatively (group D). All patients followed a routine enhanced-recovery protocol. The primary outcome measure was the total blood loss. Secondary outcome measures were hidden blood loss (HBL), reduction in the level of haemoglobin, the rate of transfusion and adverse events.


Bone & Joint 360
Vol. 7, Issue 2 | Pages 18 - 20
1 Apr 2018


The Bone & Joint Journal
Vol. 100-B, Issue 1_Supple_A | Pages 1 - 1
1 Jan 2018
Greenwald AS


The Bone & Joint Journal
Vol. 100-B, Issue 6 | Pages 712 - 719
1 Jun 2018
Batailler C Weidner J Wyatt M Dalmay F Beck M

Aims

The primary aim of this study was to define and quantify three new measurements to indicate the position of the greater trochanter. Secondary aims were to define ‘functional antetorsion’ as it relates to abductor function in populations both with and without torsional abnormality.

Patients and Methods

Three new measurements, functional antetorsion, posterior tilt, and posterior translation of the greater trochanter, were assessed from 61 CT scans of cadaveric femurs, and their reliability determined. These measurements and their relationships were also evaluated in three groups of patients: a control group (n = 22), a ‘high-antetorsion’ group (n = 22) and a ‘low-antetorsion’ group (n = 10).


Bone & Joint 360
Vol. 7, Issue 2 | Pages 28 - 30
1 Apr 2018


Bone & Joint 360
Vol. 7, Issue 2 | Pages 15 - 18
1 Apr 2018


Bone & Joint 360
Vol. 7, Issue 2 | Pages 30 - 33
1 Apr 2018


The Bone & Joint Journal
Vol. 99-B, Issue 4_Supple_B | Pages 3 - 10
1 Apr 2017
Parvizi J Shohat N Gehrke T

The World Health Organization (WHO) and the Centre for Disease Control and Prevention (CDC) recently published guidelines for the prevention of surgical site infection. The WHO guidelines, if implemented worldwide, could have an immense impact on our practices and those of the CDC have implications for healthcare policy in the United States.

Our aim was to review the strategies for prevention of periprosthetic joint infection in light of these and other recent guidelines.

Cite this article: Bone Joint J 2017;99-B(4 Supple B):3–10.


Bone & Joint 360
Vol. 6, Issue 2 | Pages 14 - 17
1 Apr 2017


Bone & Joint 360
Vol. 5, Issue 6 | Pages 32 - 34
1 Dec 2016


Bone & Joint 360
Vol. 5, Issue 5 | Pages 25 - 27
1 Oct 2016


Bone & Joint 360
Vol. 4, Issue 3 | Pages 21 - 22
1 Jun 2015

The June 2015 Spine Roundup360 looks at: Less is more in pyogenic vertebral osteomyelitis; Paracetamol out of favour in spinal pain but effective for osteoarthritis; Local wound irrigation to reduce infection?; Lumbar facet joint effusion: a reliable prognostic sign?; SPORT for the octogenarian; Neurological deterioration following traumatic spinal cord injury; PROMS in spinal surgery


Bone & Joint 360
Vol. 4, Issue 3 | Pages 29 - 30
1 Jun 2015

The June 2015 Research Roundup360 looks at: Tranexamic acid: just give it – it’s not important how!; The anterolateral ligament re-examined; Warfarin a poor post-operative agent; Passive exoskeleton the orthosis of the future?; Musculoskeletal medicine: a dark art to UK medical students?; Alendronic acid and bone density post arthroplasty; Apples with oranges? Knee functional scores revisited